Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

contast-enhanced ultrasound with sonovue

PreclinicalSmall molecule

UUniversity Hospital, Tours

contast-enhanced ultrasound with sonovue is one of 2 small molecule programs targeting Placenta Accreta. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Placenta AccretaActive, not recruiting

Placenta AccretaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Placenta Accreta

#DrugCompanyPhaseTrials

Cyklokapron

contast-enhanced ultrasound with sonovue

UUniversity Hospital, Tours

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Placenta Accreta1 trial

Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population

Completed·UUniversity Hospital, Tours·N/A·NCT02302573·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for contast-enhanced ultrasound with sonovue. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — contast-enhanced ultrasound with sonovue compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for contast-enhanced ultrasound with sonovue. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Tours company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Tours

Related News